文献速递前列腺癌

磁共振引导立体定向放疗治疗局限性前列腺癌:前瞻性2期研究患者报告结局的最终结果

Magnetic Resonance-guided Stereotactic Radiotherapy for Localized Prostate Cancer: Final Results on Patient-reported Outcomes of a Prospective Phase 2 Study.
PubMed 文献 · Eur Urol Oncol · 2020-06-12

该前瞻性2期研究纳入101例局限性前列腺癌患者,接受36.25Gy/5次磁共振引导立体定向放疗(MRgRT)。患者报告结局显示,泌尿和肠道症状在治疗前6周影响最大,至12个月恢复基线水平,无≥3级毒性。1年时仅2.2%患者报告肠道问题对日常活动有相关影响。

要点

  • MRgRT 5次SBRT后泌尿和肠道症状短暂加重,12个月恢复基线。
  • 无≥3级毒性,1年时仅2.2%患者报告肠道问题影响日常活动。
  • 83.2%患者接受雄激素剥夺治疗,限制了对性功能影响的评估。

核心结论

  • 磁共振引导立体定向放疗(MRgRT)治疗局限性前列腺癌在1年时毒性低,泌尿和肠道症状短暂且可恢复。

研究设计与样本

  • 前瞻性2期试验纳入101例局限性前列腺癌患者,全部接受36.25Gy/5次MRgRT,2周内完成。
  • 采用EORTC QLQ-C30、QLQ-PR25问卷和国际前列腺症状评分(IPSS)在基线、末次分割、6周及3、6、9、12个月评估患者报告结局,同时临床医生报告症状性不良事件。

主要发现

  • 各时间点健康相关生活质量(HRQoL)数据可用率超过95%。
  • 问卷和不良事件记录均显示,泌尿和肠道症状的最大治疗效应出现在随访前6周。
  • 此后所有症状减轻,至12个月恢复基线值。
  • 未报告≥3级毒性。
  • 1年时无患者报告因泌尿症状导致的相关限制,仅2.2%患者报告肠道问题对日常活动有相关影响。

关键数值与推荐

  • 放疗剂量为36.25Gy分5次,2周内完成。
  • 83.2%患者接受雄激素剥夺治疗(ADT)。

临床怎么用

  • 对于局限性前列腺癌,MRgRT 5次SBRT方案耐受性良好,泌尿和肠道症状短暂且1年内恢复,可用于共享决策。
  • 多数患者为中高危并接受ADT,性功能影响需进一步研究。

局限性

  • 多数患者接受ADT(83.2%),妨碍了MRgRT对性功能影响的研究。
  • 需更长期随访以评估肿瘤学结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The recent introduction of magnetic resonance-guided radiation therapy (MRgRT) has allowed improved treatment planning and delivery of stereotactic body radiotherapy (SBRT) in prostate cancer (PC). The health-related quality of life (HRQoL) outcomes using this novel approach are important in shared decision making for patients. OBJECTIVE: To report HRQoL using both patient- and clinician-reported outcomes at 1 yr following stereotactic MRgRT for patients with localized PC. DESIGN, SETTING, AND PARTICIPANTS: A prospective phase 2 trial included 101 patients with localized PC. INTERVENTION: All patients received 36.25Gy in five fractions of MRgRT delivered within 2 wk. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: HRQoL was prospectively assessed at baseline, at the last fraction, at 6 wk, and at 3, 6, 9, and 12 mo after treatment, by patient-reported outcome measures using European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-PR25 questionnaires, and International Prostate Symptom Score. At the same time points, clinicians reported on symptomatic adverse events (AEs). Effect sizes for changes in HRQoL were calculated with repeated measures analysis of variance. RESULTS AND LIMITATIONS: Availability of HRQoL data exceeded 95% at all study time points. From both questionnaires and the recorded AEs, the largest treatment effects on urinary and bowel symptoms were recorded in the first 6 wk of follow-up. Thereafter, all symptoms decreased and returned to baseline values at 12 mo. No grade ≥3 toxicity was reported. No patient reported any relevant limitation due to urinary symptoms, and only 2.2% of patients reported a relevant impact on daily activities due to bowel problems at 1 yr. The majority of patients had intermediate- or high-risk PC for which androgen deprivation therapy (83.2%) was prescribed, thereby precluding study of MRgRT on sexual function. Longer follow-up is awaited in order to evaluate the oncological outcome. CONCLUSIONS: Delivery of MRgRT for SBRT resulted in low toxicity at 1 yr. PATIENT SUMMARY: All patients completed magnetic resonance-guided radiation therapy, which was well tolerated with only transient early urinary and bowel symptoms, which resolved 1 yr after treatment, as confirmed by patient-reported outcome measures.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Tetar SU, Bruynzeel AME, Oei SS, et al. Magnetic Resonance-guided Stereotactic Radiotherapy for Localized Prostate Cancer: Final Results on Patient-reported Outcomes of a Prospective Phase 2 Study. Eur Urol Oncol. 2020. PMID: 32536573. doi:10.1016/j.euo.2020.05.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。